https://www.vice.com/en_us/article/y3wkjj/psychedelics-nonprofit-raises-dollar100-million-in-push-to-legalize-selling-mdma-for-ptsd

A key player in the competitive pharmaceutical psychedelics industry has raised over $100 million to fund a final push to get government approval to legally sell MDMA in the U.S. to those struggling with post-traumatic stress disorder.  

The nonprofit Multidisciplinary Association for Psychedelic Studies, or MAPS, raised the money in a Series A funding round through a subsidiary previously known as the MAPS Public Benefit Corporation, or MAPS PBC. In a release on Friday announcing the news of the cash infusion, the organization also said it was renaming the public benefit company Lykos Therapeutics.